Quarter
Charts
πŸ‡ΊπŸ‡ΈUS Markets

BIO-TECHNE CORPORATION

TECH

CIK 0000842023 Β· Quarterly mode Β· latest period FY2025 (Q4) (ending 2025-12-31) Β· sourced from SEC EDGAR

At a glance Β· FY2025 (Q4)

Revenue
$296M
↓-0.4% -$1Mvs FY2024 (Q4)
Operating Income
$54M
↑+14.9% +$7Mvs FY2024 (Q4)
Net Income
$38M
↑+8.9% +$3Mvs FY2024 (Q4)
Gross Profit
$191M
↓-1.3% -$3Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot Β· latest annual filed values Β· S&P 500 calibration

Poor
28/100
  • Profitability
    0ROIC 3.9% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 4.54 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    21Asset Turnover 0.47x (1.0+ = capital-efficient)
  • Growth
    15Revenue YoY -0.4% (10% = solid, 25%+ = elite)
  • Margin Trend
    34Op Margin 18.4% Β· trend -0.9pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project TECH's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

3%

Trailing 3-yr CAGR was -2.9%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≀ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$22.42
Total enterprise IV
$3.58B
Diluted shares
0.16B
Terminal PV
$2.52B (70% of total)
Year-5 FCF
$297M
YearProjected FCFDiscounted PV
+1$264M$240M
+2$272M$225M
+3$280M$211M
+4$289M$197M
+5$297M$185M
Terminal$4.06B$2.52B

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target β€” and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation Β· trailing 4 quarters

how the company spent its cash
Capex (TTM)
$26M
investment in PP&E
Dividends paid (TTM)
$50M
cash returned to holders
Stock buybacks (TTM)
$200M
share count reduction
Stock-based comp (TTM)
$42M
non-cash dilution

Balance sheet Β· 2025-12-31

latest filed snapshot
Total assets
$2.52B
everything owned
Stockholders' equity
$2.01B
shareholder claim

Recent performance Β· 66 quarters

Revenue↓-0.4% -$1M
$296M
Net Income↑+8.9% +$3M
$38M
Free Cash Flow↓-1.3% -$1M
$76M
Operating Margin↑+2.4pts
18.4%

Drill down